Home>>Signaling Pathways>> Neuroscience>> Ophthalmology>>Prostaglandin F2α ethyl amide

Prostaglandin F2α ethyl amide (Synonyms: Dinoprost ethyl amide, PGF2αNEt)

Catalog No.GC44723

Prostaglandin F2α ethyl amide (PGF2α-NEt) is an analog of PGF2α in which the C-1 carboxyl group has been modified to an N-ethyl amide.

Products are for research use only. Not for human use. We do not sell to patients.

Prostaglandin F2α ethyl amide Chemical Structure

Cas No.: 54130-36-8

Size Price Stock Qty
1mg
$72.00
In stock
5mg
$324.00
In stock
10mg
$576.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Prostaglandin F2α ethyl amide (PGF2α-NEt) is an analog of PGF2α in which the C-1 carboxyl group has been modified to an N-ethyl amide. PG esters have been shown to have ocular hypotensive activity. PG N-ethyl amides were recently introduced as alternative prostaglandin ocular hypotensive prodrugs. Although it has been claimed that PG ethyl amides are not converted to the free acids in vivo, studies in our laboratories have shown that bovine and human corneal tissue converts the N-ethyl amides of various prostaglandins to the free acids with a conversion rate of about 2.5 µg/g corneal tissue/hr. PGF2α-NEt would be expected to show the typical intraocular effects of PGF2α free acid, but with the much slower hydrolysis pharmacokinetics of the PG N-amides.

Reviews

Review for Prostaglandin F2α ethyl amide

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Prostaglandin F2α ethyl amide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.